LILRB1 (ILT2)
LILRB1 is a brake on macrophages, dendritic cells and some NK and T cells that reads ordinary HLA class I, so any cell showing HLA is protected. Antibodies that block it, with or without LILRB2, are in early trials.
Overview
LILRB1 (chromosome 19q13.42) is a receptor for class I MHC antigens that recognises a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles and the cytomegalovirus homologue UL18; ligand binding gives inhibitory signals and down-regulates the immune response, and engagement on NK or T cells protects the target from lysis. It is expressed in B cells, monocytes and myeloid, plasmacytoid and tolerogenic dendritic cells, in decidual macrophages and decidual NK cells (protein level) (UniProt Q8NHL6). NGM707, an antibody against LILRB1 and LILRB2, was studied in phase 1/2 with pembrolizumab (NCT04913337); a later phase 2 study was withdrawn by the sponsor (NCT07511972).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · LILRB1 is a brake on macrophages, dendritic cells and some NK and T cells that reads ordinary HLA class I, so any cell showing HLA is protected. Antibodies that block it, with or without LILRB2, are in early trials.
- 1 · What it is
LILRB1 is a brake on macrophages, dendritic cells and some NK and T cells that reads ordinary HLA class I, so any cell showing HLA is protected. Antibodies that block it, with or without LILRB2, are in early trials.
- 2 · What goes wrong in cancer
An ITIM-bearing LILR; LILRB receptors negatively regulate myeloid maturation and permit a suppressive myeloid phenotype in tumours (van der Touw et al. 2017).
- 3 · How drugs use it
No product in this corpus aims at LILRB1 (ILT2) yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
External identifiers
Sources: HGNC HGNC:6605 (approved symbol, name, aliases and cross-references); UniProt Q8NHL6 (protein name, function and tissue specificity)
Biology
An ITIM-bearing LILR; LILRB receptors negatively regulate myeloid maturation and permit a suppressive myeloid phenotype in tumours (van der Touw et al. 2017).
- B cells, monocytes, dendritic cells, decidual macrophages and NK cells (UniProt Q8NHL6)
Notes
top- Prevalence not recorded: HGNC and UniProt carry no positivity rates.
Latest papers
topQuery for this target: (TITLE:"LILRB1" OR ABSTRACT:"LILRB1" OR TITLE:"ILT2" OR ABSTRACT:"ILT2" OR TITLE:"LIR-1" OR ABSTRACT:"LIR-1" OR TITLE:"CD85j" OR ABSTRACT:"CD85j" OR TITLE:"leukocyte immunoglobulin like receptor B1" OR ABSTRACT:"leukocyte immunoglobulin like receptor B1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LILRB1 (ILT2), not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetHLA-E
Shares HLA-A, The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetTDO2
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetOX40 (TNFRSF4)
Shares The cancer-immunity cycle, Checkpoint (two meanings), Pembrolizumab and the tag checkpoint-map.
- TargetCD39 (ENTPD1)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetHHLA2 (B7-H7)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetGITR (TNFRSF18)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD27
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetAdenosine A2A receptor (ADORA2A)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.